ECCMID
The partnership, announced last week just before ECCMID kicked off, is the first major foray for both companies into the sequencing-based infectious disease diagnostics market.
The firm's planned launches include a respiratory virus panel, a gastrointestinal panel, and a fingerstick tuberculosis test, it revelaed this week at ECCMID.
Multicenter Study Finds BioFire Joint Infection Panel Shows High Accuracy Despite Limitations
Premium
The assay received de novo authorization from the US Food and Drug Administration and CE-IVD marking last year.
The company will launch 37 CE-IVD-marked assays this year, mostly for infectious diseases, for use on the QuantStudio 5 Dx and eventually QuantStudio 7 Pro Dx platforms.
Molecular TB Assay From PBD Biotech Shows Promise in Detecting Latent-to-Active Disease Risk
Premium
The blood-based assay, called Actiphage, combines phage-induced lysis of infectious bacteria and molecular detection of bacterial DNA.
Apr 25, 2022
Apr 19, 2019
Apr 15, 2019
Apr 24, 2018
Apr 23, 2018